Fabio Ynoe de Moraes1, Heloisa de Andrade Carvalho2, Samir Abdallah Hanna1, João Luis Fernandes da Silva1, Gustavo Nader Marta3. 1. Department of Radiation Oncology, Hospital Sírio-Libânes, São Paulo, SP, Brazil. 2. Department of Radiation Oncology, Hospital Sírio-Libânes, São Paulo, SP, Brazil ; Radiotherapy - Department of Radiology and Oncology, Radiology Institute - InRad, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil. 3. Department of Radiation Oncology, Hospital Sírio-Libânes, São Paulo, SP, Brazil ; Department of Radiation Oncology, Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, SP, Brazil.
Abstract
BACKGROUND: Mycosis fungoides (MF) is an extranodal, indolent non-Hodgkin lymphoma of T cell origin. Even with the establishment of MF staging, the initial treatment strategy often remains unclear. AIM: The aim of this study was to review the clinical results of total skin electron beam therapy (TSEBT) for MF in adults published in English language scientific journals searched in Pubmed/Medline database until December 2012. RESULTS: MF is very sensitive to radiation therapy (RT) delivered either by photons or by electrons. In limited patches and/or plaques local electron beam irradiation results in good outcomes besides the fact of not being superior to other modalities. For extensive patches and/or plaques data suggest that TSEBT shows superior response rates. The cutaneous disease presentation is favorably managed with radiotherapy due to its ability to treat the full thickness of deeply infiltrated skin. For generalized erythroderma presentation, TSEBT seems to be an appropriate initial therapy. For advanced disease, palliation, or recurrence after the first radiotherapy treatment course, TSEBT may still be beneficial, with acceptable toxicity. Recommended dose is 30-36 Gy delivered in 6-10 weeks. CONCLUSION: TSEBT can be used to treat any stage of MF. It also presents good tumor response with symptoms of relief and a palliative effect on MF, either after previous irradiation or failure of other treatment strategies.
BACKGROUND:Mycosis fungoides (MF) is an extranodal, indolent non-Hodgkin lymphoma of T cell origin. Even with the establishment of MF staging, the initial treatment strategy often remains unclear. AIM: The aim of this study was to review the clinical results of total skin electron beam therapy (TSEBT) for MF in adults published in English language scientific journals searched in Pubmed/Medline database until December 2012. RESULTS: MF is very sensitive to radiation therapy (RT) delivered either by photons or by electrons. In limited patches and/or plaques local electron beam irradiation results in good outcomes besides the fact of not being superior to other modalities. For extensive patches and/or plaques data suggest that TSEBT shows superior response rates. The cutaneous disease presentation is favorably managed with radiotherapy due to its ability to treat the full thickness of deeply infiltrated skin. For generalized erythroderma presentation, TSEBT seems to be an appropriate initial therapy. For advanced disease, palliation, or recurrence after the first radiotherapy treatment course, TSEBT may still be beneficial, with acceptable toxicity. Recommended dose is 30-36 Gy delivered in 6-10 weeks. CONCLUSION:TSEBT can be used to treat any stage of MF. It also presents good tumor response with symptoms of relief and a palliative effect on MF, either after previous irradiation or failure of other treatment strategies.
Entities:
Keywords:
Electron beam therapy; Mycosis fungoides; Radiotherapy; Total skin irradiation
Authors: Gustavo Nader Marta; Carolina Bueno de Gouvêa; Stéfani Bertolucci Estevam Ferreira; Samir Abdallah Hanna; Cecília Maria Kalil Haddad; João Luis Fernandes da Silva Journal: An Bras Dermatol Date: 2011 May-Jun Impact factor: 1.896
Authors: Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Glenn W Jones; Barry M Kacinski; Lynn D Wilson; Rein Willemze; Margaret Spittle; Gerda Hohenberg; Leonore Handl-Zeller; Franz Trautinger; Robert Knobler Journal: J Am Acad Dermatol Date: 2002-09 Impact factor: 11.527
Authors: Timothy C Zhu; Yihong Ong; Hongjin Sun; Weili Zhong; Tianshun Miao; Andreea Dimofte; Petr Bruza; Amit Maity; John P Plastaras; Ima Paydar; Lei Dong; Brian W Pogue Journal: Proc SPIE Int Soc Opt Eng Date: 2021-03-30
Authors: Jacqueline M Andreozzi; Rongxiao Zhang; David J Gladstone; Benjamin B Williams; Adam K Glaser; Brian W Pogue; Lesley A Jarvis Journal: Med Phys Date: 2016-02 Impact factor: 4.071
Authors: Yunhe Xie; Heather Petroccia; Amit Maity; Tianshun Miao; Yihua Zhu; Petr Bruza; Brian W Pogue; John P Plastaras; Lei Dong; Timothy C Zhu Journal: Med Phys Date: 2019-11-26 Impact factor: 4.071
Authors: Eric M Schaff; Stephen A Rosenberg; Stephanie J Olson; Steven P Howard; Kristin A Bradley Journal: Radiat Oncol Date: 2018-04-13 Impact factor: 3.481
Authors: Elizabeth B Jeans; Yue-Houng Hu; Bradley J Stish; Brian King; Mark Davis; William S Harmsen; Kristin M Fruth; Sarah E Locher; Christopher L Deufel; Jaden D Evans; James A Martenson; Scott C Lester Journal: Pract Radiat Oncol Date: 2020-08-08